Graybug Vision has closed $80 million in Series C financing, which will be used to advance its pan-VEGF inhibitor GB-102 into phase 2 studies and its potential glaucoma treatment GB-401 into the clinic, according to a press release.
The financing was led by CBC Group and includes participation from Deerfield Management, OrbiMed Advisors and Hatteras Venture Partners.
A phase 2b clinical study of GB-102, a potential twice-a-year treatment, is planned for the treatment of wet age-related macular degeneration, as well as a phase 2a study for macular edema secondary to (Read more...)
Uncategorized